COINS Act & BINSA: What Chinese Biopharma Leaders Need to Know
An in-depth analysis of the COINS Act and BINSA and their implications for innovation, licensing, investment, and global collaboration.
The first episode of NAPPA Healthcare & Biopharma Insights, NAPPA’s signature thought-leadership webinar series, opens with a focused analysis of two pieces of U.S. legislation reshaping the cross-border biopharma landscape: the COINS Act and BINSA.
Patent attorney Frank Gao (Ladas & Parry LLP), NAPPA’s Midwest Regional Director, leads a one-hour briefing on the legal, IP, and strategic implications for Chinese biopharma companies operating across the U.S.–China corridor — including licensing, technology transfer, investment, and risk mitigation.
The session is open to NAPPA members, partners, and qualified industry guests. Register below to receive Zoom join details.
Key topics.
- ✓ What is the COINS Act?
- ✓ What is BINSA?
- ✓ Impact on Chinese Biopharma Companies
- ✓ Licensing, Technology Transfer & IP Strategy
- ✓ Cross-Border Investment Outlook
- ✓ Opportunities and Risk Mitigation
Understand U.S. legislative developments shaping the cross-border biopharma environment.
Assess the operational implications for biopharma innovation, licensing, and investment.
Navigate global partnerships and U.S. market access with a clear legal lens.
Reserve your seat.
Registration is free for NAPPA members and qualified industry guests. Join details will be sent to your email immediately after registering.